Type I interferon pathway genetic variants in severe COVID-19

被引：2
作者：
Montenegro, A. F. L. [1 ]
Clementino, M. A. F. [2 ]
Yaochite, J. N. U. [1 ]
机构：
[1] Univ Fed Ceara UFC, Fac Farm Odontol & Enfermagem, Dept Anal Clin & Toxicol, Lab Imunol Celular & Mol, Rua Pastor Samuel Munguba 1210, Fortaleza, Ceara, Brazil
[2] Univ Fed Ceara UFC, Lab Toxinol Mol, NUBIMED Nucleo Biomed, Fortaleza, Ceara, Brazil
来源：
VIRUS RESEARCH | 2024年 / 342卷
关键词：
COVID-19; Type I interferon; Single nucleotide polymorphisms; SUSCEPTIBILITY; IMMUNITY; INNATE;
D O I：
10.1016/j.virusres.2024.199339
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
Coronavirus Disease 2019 (COVID-19) is an infectious disease caused by SARS-CoV-2. According to the World Health Organization (WHO), there have been over 760 million reported cases and over 6 million deaths caused by this disease worldwide. The severity of COVID-19 is based on symptoms presented by the patient and is divided as asymptomatic, mild, moderate, severe, and critical. The manifestations are interconnected with genetic variations. The innate immunity is the quickest response mechanism of an organism against viruses. Type I interferon pathway plays a key role in antiviral responses due to viral replication inhibition in infected cells and adaptive immunity stimulation induced by interferon molecules. Thus, variants in type I interferon pathway's genes are being studied in different COVID-19 manifestations. This review summarizes the role of variants in type I interferon pathway's genes on prognosis and severity progression of COVID-19.
引用
收藏
页数：9
相关论文
共 50 条
  • [31] Specialized interferon action in COVID-19
    Galbraith, Matthew D.
    Kinning, Kohl T.
    Sullivan, Kelly D.
    Araya, Paula
    Smith, Keith P.
    Granrath, Ross E.
    Shaw, Jessica R.
    Baxter, Ryan
    Jordan, Kimberly R.
    Russell, Seth
    Dzieciatkowska, Monika
    Reisz, Julie A.
    Gamboni, Fabia
    Cendali, Francesca
    Ghosh, Tusharkanti
    Guo, Kejun
    Wilson, Cara C.
    Santiago, Mario L.
    Monte, Andrew A.
    Bennett, Tellen D.
    Hansen, Kirk C.
    Hsieh, Elena W. Y.
    D'Alessandro, Angelo
    Espinosa, Joaquin M.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2022, 119 (11)
  • [32] Therapeutic Options for Coronavirus Disease 2019 (COVID-19)-Modulation of Type I Interferon Response as a Promising Strategy?
    Mary, Aurelien
    Henaut, Lucie
    Schmit, Jean-Luc
    Lanoix, Jean-Philippe
    Brazier, Michel
    FRONTIERS IN PUBLIC HEALTH, 2020, 8
  • [33] Do genetic variants of the Y chromosome affect mortality from COVID-19
    Lenning, Ole Bernt
    Myhre, Ronny
    Vadla, May Sissel
    Omdal, Roald
    Jarreta, Begona Martinez
    Moreno, Angel Gomez
    De Blas, Ignacio
    Braut, Geir Sverre
    SCANDINAVIAN JOURNAL OF PUBLIC HEALTH, 2025,
  • [34] Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19
    Daniela Matuozzo
    Estelle Talouarn
    Astrid Marchal
    Peng Zhang
    Jeremy Manry
    Yoann Seeleuthner
    Yu Zhang
    Alexandre Bolze
    Matthieu Chaldebas
    Baptiste Milisavljevic
    Adrian Gervais
    Paul Bastard
    Takaki Asano
    Lucy Bizien
    Federica Barzaghi
    Hassan Abolhassani
    Ahmad Abou Tayoun
    Alessandro Aiuti
    Ilad Alavi Darazam
    Luis M. Allende
    Rebeca Alonso-Arias
    Andrés Augusto Arias
    Gokhan Aytekin
    Peter Bergman
    Simone Bondesan
    Yenan T. Bryceson
    Ingrid G. Bustos
    Oscar Cabrera-Marante
    Sheila Carcel
    Paola Carrera
    Giorgio Casari
    Khalil Chaïbi
    Roger Colobran
    Antonio Condino-Neto
    Laura E. Covill
    Ottavia M. Delmonte
    Loubna El Zein
    Carlos Flores
    Peter K. Gregersen
    Marta Gut
    Filomeen Haerynck
    Rabih Halwani
    Selda Hancerli
    Lennart Hammarström
    Nevin Hatipoğlu
    Adem Karbuz
    Sevgi Keles
    Christèle Kyheng
    Rafael Leon-Lopez
    Jose Luis Franco
    Genome Medicine, 15
  • [35] Immunopathogenesis and Immunogenetic Variants in COVID-19
    Sagulkoo, Pakorn
    Plaimas, Kitiporn
    Suratanee, Apichat
    Simao, Andrea Name Colado
    Reiche, Edna Maria Vissoci
    Maes, Michael
    CURRENT PHARMACEUTICAL DESIGN, 2022, 28 (22) : 1780 - 1797
  • [36] COVID-19 Variants and Vaccine Development
    Zhao, Ziyao
    Bashiri, Sahra
    Ziora, Zyta M.
    Toth, Istvan
    Skwarczynski, Mariusz
    VIRUSES-BASEL, 2024, 16 (05):
  • [37] Laboratory and genetic predictors for severe COVID-19 infection
    Kadiyska, Tanya
    Cherneva, Radostina
    Cherneva, Zheina
    Marchev, Sotir
    Madzharova, Dilyana
    Tourtourikov, Ivan
    Mitev, Vanyo
    PHARMACIA, 2024, 71 : 1 - 8
  • [38] Genetic Screening for TLR7 Variants in Young and Previously Healthy Men With Severe COVID-19
    Solanich, Xavier
    Vargas-Parra, Gardenia
    van der Made, Caspar I.
    Simons, Annet
    Schuurs-Hoeijmakers, Janneke
    Antoli, Arnau
    del Valle, Jesus
    Rocamora-Blanch, Gemma
    Setien, Fernando
    Esteller, Manel
    van Reijmersdal, Simon V.
    Riera-Mestre, Antoni
    Sabater-Riera, Joan
    Capella, Gabriel
    van de Veerdonk, Frank L.
    van der Hoven, Ben
    Corbella, Xavier
    Hoischen, Alexander
    Lazaro, Conxi
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [39] The Role of Type I Interferons in the Pathogenesis and Treatment of COVID-19
    Schreiber, Gideon
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [40] COVID-19 Genetic Variants and Their Potential Impact in Vaccine Development
    Giau Van Vo
    Bagyinszky, Eva
    An, Seong Soo A.
    MICROORGANISMS, 2022, 10 (03)
12345